Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.57 |
| ▸ | CNR2 | P34972 | 6/20 | 0.51 |
| ▸ | ATR | Q13535 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129802 | 0.81 | ALOX5 (0.57) | NPC1RAB9AMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL28528175 | 0.81 | ADK (0.47) | ADKCNR2ATR | |
| SCHEMBL21495017 | 0.79 | AR (0.50) | NPC1RAB9AMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL24170032 | 0.77 | AR (0.48) | ADKNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL19899542 | 0.76 | SMN1; SMN2 (0.54) | NPC1RAB9ASMN1; SMN2MEN1LMNA | |
| SCHEMBL29654073 | 0.76 | CYP1A1 (0.61) | NPC1RAB9AMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL13815773 | 0.75 | CNR2 (0.53) | ADKCNR2ATR | |
| SCHEMBL7294070 | 0.74 | CNR2 (0.62) | CNR2SMN1; SMN2MEN1LMNAMAPT | |
| SCHEMBL17407205 | 0.74 | RAB9A (0.49) | NPC1RAB9AMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL12293461 | 0.74 | RAB9A (0.52) | NPC1RAB9AMAPK1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2023-02-21 | — | — | US | disclosed |
| US-20220002282-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2022-01-06 | — | — | US | disclosed |
| CN-112313229-A | Substituted aminothiazoles as inhibitors of nucleases | 马萨里克大学 | 2021-02-02 | — | — | CN | disclosed |
| WO-2019201865-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019201865-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2019-10-24 | — | — | WO | disclosed |
| US-20020177594-A1 | Inhibitors of histone deacetylase | ABBOTT LABORATORIES | 2002-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | RNASEH1, DNASE1, FEN1 | ADK 1481/4885CNR2 4825/4885ATR 605/4885 |
| US-20020177594-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC3 | ADK 3710/4885CNR2 4785/4885ATR 2981/4885 |
| US-20220002282-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | RNASEH1, DNASE1, FEN1 | ADK 1481/4885CNR2 4825/4885ATR 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.